Paper Details

  1. Home
  2. Paper Details

Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines.

Author: MasudaUtako, MatsumotoAyaka, MinegakiTetsuya, MiyamotoKeisuke, MoriyamaYumi, NishiguchiKohshi, OtaKeisuke, TanahashiMami, TanakaMai, TsujimotoMasayuki, WadaAkari, YamamotoAyaka

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, enhances the cytotoxicity of various anticancer drugs. This study examined the effect of olaparib on the cytotoxicity of anticancer drugs in esophageal squamous cell carcinoma (ESCC) cell lines, suggesting that olaparib may be a potential secondary treatment option for ESCC.
Paper Details　
Original Abstract of the Article :
Chemotherapy is an important first-line treatment for oesophageal squamous cell carcinoma (ESCC). However, there are few secondary options. Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, enhances the cytotoxicity of various anticancer drugs and has been used to treat advanced ovarian and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.21873/anticanres.13288

データ提供：米国国立医学図書館（NLM）

Synergistic Effects of Olaparib and DNA-Damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines

This study investigates the potential synergistic effects of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and DNA-damaging agents in treating oesophageal squamous cell carcinoma (ESCC). The study examines the effects of olaparib on the cytotoxicity of anticancer drugs in ESCC cell lines. The researchers found that olaparib enhances the cytotoxicity of various anticancer drugs, suggesting its potential as a treatment option for ESCC.

Uncovering New Avenues: Olaparib as a Potential Treatment for ESCC

The study highlights the potential of olaparib, a PARP inhibitor, as a treatment for ESCC. The researchers demonstrated that olaparib enhances the cytotoxicity of various anticancer drugs, suggesting its potential use in combination therapies for ESCC. These findings offer hope for new treatment strategies for this challenging disease.

Hope on the Horizon: Innovative Approaches to Cancer Treatment

The study underscores the importance of exploring innovative approaches to cancer treatment. The researchers' findings suggest that olaparib, a PARP inhibitor, could be a valuable addition to the arsenal of cancer treatments, particularly for ESCC. This research opens up exciting possibilities for improving patient outcomes and offers a glimmer of hope for those battling this disease.

Dr.Camel's Conclusion

This research sheds light on the potential of olaparib as a promising treatment for ESCC. By exploring the synergistic effects of olaparib and DNA-damaging agents, the study offers a beacon of hope in the fight against this challenging disease. As we continue to explore the vast and intricate landscape of cancer research, we can use these findings to develop new treatment strategies and offer better outcomes for patients.

Date :
  1. Date Completed 2019-04-23
  2. Date Revised 2019-08-16
Further Info :

Pubmed ID

30952721

DOI: Digital Object Identifier

10.21873/anticanres.13288

Related Literature

Article Analysis
・Effects of olaparib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.